Myeloma bone disease: Progress in pathogenesis

被引:6
|
作者
Xi, Hao [1 ]
An, Ran [1 ]
Li, Lu [1 ]
Wang, Gang [2 ]
Tao, Yi [3 ]
Gao, Lu [2 ]
机构
[1] Second Mil Med Univ, Changzheng Hosp, Myeloma & Lymphoma Ctr, Dept Hematol, Shanghai, Peoples R China
[2] Second Mil Med Univ, Dept Physiol, 800 Xiangyin Rd, Shanghai 200433, Peoples R China
[3] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Hematol, Shanghai, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
Myeloma bone disease; Osteoblast; Osteoclast; Osteoclast cell activating factor; Osteoblast cell inactivating factor; MULTIPLE-MYELOMA; OSTEOCLAST FORMATION; GROWTH-FACTOR; IN-VITRO; OSTEOBLAST DIFFERENTIATION; CELL-PROLIFERATION; TUMOR BURDEN; INHIBITION; ACTIVATION; EXPRESSION;
D O I
10.1016/j.pbiomolbio.2016.08.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Myeloma bone disease (MBD) is one of the most serious complications of multiple myeloma (MM) and the most severe cause of MM morbidity. Dysregulation of osteoblast and osteoclast cells plays key roles in MBD. In the bone marrow microenvironment, myeloma cells, osteoblasts, osteoclasts and bone marrow stromal cells can secrete multiple cytokines, categorized as osteoclast cell activating factors (OAFS) and osteoblast cell inactivating factors, which have been discovered to participate in bone metabolism and contribute to the pathogenesis of MBD. Several signaling pathways related to these cytokines were also revealed in the MBD pathogenesis. To better understand the pathogenesis of MBD and therefore the potential therapeutic targets of this disease, we will summarize recent study progress in the factors and underlying signaling pathways involved in the occurrence and development of MBD. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:149 / 155
页数:7
相关论文
共 50 条
  • [21] SERUM PROINFLAMMATORY CYTOKINES PROFILE IN MULTIPLE MYELOMA RELATED TO PATHOGENESIS OF BONE DISEASE
    Gervas-Arruga, J.
    Pocovi, M.
    Giraldo, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 571 - 571
  • [22] Pathogenesis and management of bone lesions in multiple myeloma
    Bataille, R
    Manolagas, SC
    Berenson, JR
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1997, 11 (02) : 349 - +
  • [23] Myeloma and Bone Disease
    Cristina Panaroni
    Andrew J. Yee
    Noopur S. Raje
    Current Osteoporosis Reports, 2017, 15 : 483 - 498
  • [24] Myeloma bone disease
    Matsumoto, T.
    BONE, 2011, 48 : S57 - S58
  • [25] Myeloma and Bone Disease
    Panaroni, Cristina
    Yee, Andrew J.
    Raje, Noopur S.
    CURRENT OSTEOPOROSIS REPORTS, 2017, 15 (05) : 483 - 498
  • [26] Bone disease in myeloma
    Berenson J.R.
    Current Treatment Options in Oncology, 2001, 2 (3) : 271 - 283
  • [27] Myeloma bone disease
    Callander, NS
    Roodman, GD
    SEMINARS IN HEMATOLOGY, 2001, 38 (03) : 276 - 285
  • [28] Myeloma Bone Disease
    Sanderson, Ralph D.
    Epstein, Joshua
    JOURNAL OF BONE AND MINERAL RESEARCH, 2009, 24 (11) : 1783 - 1788
  • [29] Myeloma bone disease
    Sezer, O
    HEMATOLOGY, 2005, 10 : 19 - 24
  • [30] Myeloma bone disease
    Berenson, JR
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (04) : 653 - 672